OBR Daily Commentary

forumImage

Integration of Smoking Cessation Program within CT Lung Cancer Screening Program Shows Life-Saving and Cost-Effective Results

(WCLC) Oct 16, 2017 - A study that integrated robust smoking cessation programs into an organized low-dose CT (LDCT) lung cancer screening program found that the inclusion of both interventions has the potential to decrease mortality rates while being relatively cost-effective.

Read Article arrow

Winston Wong, PharmD (Posted: October 19, 2017)

quotesFrom the payer standpoint, there is a belief that smoking cessation programs work to some degree. At one time, it was even a requirement to participate in a program when coverage for smoking cessation products were requested to be covered. However the results were spotty. The success rate was low, driven by the overall member motivation to take the program seriously and successfully complete the program. If we focus on that small piece of the population, the ROI is significant. But looking at it from an overall standpoint, the ROI is not as impressivequotes

Add Comment 1 Comment
forumImage

Take the Generic, Patients Are Told. Until They Are Not.

(New York Times/ProPublica) Aug 6, 2017 - Consumers have grown used to being told to give up their brand-name drugs in favor of cheaper generics. Now some are finding the opposite is true.

Read Article arrow

Winston Wong, PharmD (Posted: August 14, 2017)

quotesThe rationale is pretty simple. The branded drugs are now presenting deep rebate discounts, and bring the net cost to somewhere comparable to the generic/biosimilar. If the cheaper drug was dispensed outright, the only win is the patient paying the lower copay and payer experiences an immediate cost savings. If the more expensive brand is dispensed, the PBM/Payer get the rebate, of which the PBM receives a portion of, and hopefully the piece of the rebate that is passed through to the payer will bring the cost down, if they can even track it. So in essence, that final statement is very true. Someone has to be making money from the deal to make it fly.quotes

Add Comment 1 Comment
forumImage

Opinion: Who Is To Blame For Skyrocketing Drug Prices?

(The Hill) July 27, 2017 - Across the board, drug prices are soaring. Even the cost of cancer medications are so high that some patients are delaying cancer treatments or skipping them altogether.

Read Article arrow

Winston Wong, PharmD (Posted: August 04, 2017)

quotesThe finger pointing between Pharma and the PBM's is looking much like the political arena with regards to ACA. In all reality, both are stockholders and both contribute to the high cost of drugs. The last factor that no one is considering is that whatever, and wherever the price is set at, we will reimburse. That is not the case in Europe, especially in the countries mentioned. In those countries, if the price is too high, the drug is not reimbursed. quotes

Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...